Processa Pharmaceuticals secures licensing agreement with Intact Therapeutics for PCS12852, including significant milestone payments and royalties.
Quiver AI Summary
Processa Pharmaceuticals, Inc. has announced a licensing agreement with Intact Therapeutics for PCS12852, a novel 5-HT4 receptor agonist aimed at treating gastroparesis and gastrointestinal motility disorders. The deal includes potential milestone payments totaling $452.5 million, with $2.5 million due shortly after the option is exercised, and a double-digit royalty on future sales, excluding South Korea. Processa will retain a 3.5% equity stake in Intact and will share 60% of its cash payments with its licensor. The partnership is seen as a way to leverage Processa's non-oncology assets while contributing to Intact's goal of addressing significant unmet needs in gastrointestinal treatments. PCS12852 has shown promising safety and efficacy in previous clinical trials, highlighting its potential as a leading treatment option for patients.
Potential Positives
- $452.5 million in total milestone payments potentially strengthens Processa's financial position and supports future growth initiatives.
- Receipt of a $2.5 million near-term payment provides immediate liquidity to the company.
- Double-digit royalties on future net product sales could generate ongoing revenue, enhancing the value of the partnership.
- The equity stake in Intact Therapeutics aligns Processa with a promising partner in the gastrointestinal market, which may lead to strategic collaboration and shared success.
Potential Negatives
- Processa Pharmaceuticals must share 60% of any cash payments from Intact with its licensor, significantly reducing the financial benefit from the agreement.
- The partnership may indicate a strategic shift away from their primary focus on oncology therapies, potentially leading to questions about the company’s core direction and commitment to its original mission.
FAQ
What is the total value of milestone payments in the agreement with Intact Therapeutics?
The total value of milestone payments is $452.5 million.
What is the initial payment Processa Pharmaceuticals will receive?
Processa Pharmaceuticals will receive a $2.5 million near-term payment as part of the agreement.
What royalties will Processa earn from the partnership?
Processa will earn double-digit royalties on future worldwide net product sales, excluding South Korea.
What is PCS12852 designed to treat?
PCS12852 is designed to treat gastroparesis and other gastrointestinal motility disorders.
Who are the key executives mentioned in the press release?
George Ng, CEO of Processa, and Ravi Pamnani, CEO and Co-Founder of Intact Therapeutics, are key executives mentioned.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PCSA Insider Trading Activity
$PCSA insiders have traded $PCSA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PCSA stock by insiders over the last 6 months:
- DAVID YOUNG (Pres. Research & Development) purchased 124,500 shares for an estimated $99,288
- GEORGE K NG (Chief Executive Officer) purchased 87,200 shares for an estimated $69,542
- PATRICK LIN (Chief Business - Strategy Off) purchased 43,500 shares for an estimated $34,691
- JUSTIN W YORKE purchased 12,400 shares for an estimated $9,889
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCSA Hedge Fund Activity
We have seen 5 institutional investors add shares of $PCSA stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 56,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $20,720
- VIRTU FINANCIAL LLC added 43,229 shares (+inf%) to their portfolio in Q1 2025, for an estimated $15,994
- HRT FINANCIAL LP removed 31,971 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $11,829
- GEODE CAPITAL MANAGEMENT, LLC added 12,431 shares (+56.6%) to their portfolio in Q1 2025, for an estimated $4,599
- UBS GROUP AG removed 7,852 shares (-99.3%) from their portfolio in Q1 2025, for an estimated $2,905
- ALLWORTH FINANCIAL LP removed 85 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $75
- BANK OF AMERICA CORP /DE/ added 12 shares (+48.0%) to their portfolio in Q1 2025, for an estimated $4
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- $452.5 million in total milestone payments
- $2.5 million in near-term payments
- Double-digit royalties on future net product sales
- 3.5% equity stake in Intact Therapeutics
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) , today announced that it has entered into a binding term sheet with Intact Therapeutics, Inc. (“Intact”) granting Intact the exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis and other gastrointestinal motility disorders.
Under the terms of the agreement, Processa is eligible to receive a $2.5 million option exercise fee, up to $20 million in development and regulatory milestone payments and over $432.5 million in commercial milestone payments based on net product sales. Intact will also pay Processa a double-digit royalty on worldwide net sales of licensed products, excluding South Korea, and provide Processa with an equity stake in Intact upon closing. Under the terms of its license, Processa must share 60% of any cash payments with its licensor (excluding the equity stake in Intact).
“This agreement is another example of how we can unlock the value of our non-oncology assets while remaining laser-focused on our mission of developing next-generation cancer therapies,” said George Ng, CEO of Processa. “We believe Intact’s innovative delivery platform and GI-focused strategy make them an ideal partner to advance PCS12852 toward commercialization. PCS12852 has demonstrated a favorable safety and efficacy profile in clinical studies and represents a highly differentiated, potentially best-in-class approach for patients suffering from gastroparesis and other gastrointestinal disorders.”
“At Intact, we are building a company around the idea that there remain significant unmet clinical needs in GI — not only to treat disease but also to radically improve patient quality of life,” added Ravi Pamnani, CEO and Co-Founder of Intact Therapeutics. “PCS12852’s strong clinical data in improving gastric motility and clean safety profile make it an ideal candidate to add to our GI portfolio. We are thrilled to partner with Processa and advance this asset through our development pipeline.”
PCS12852 is a selective 5-HT4 receptor agonist that completed a Phase 2a trial demonstrating strong safety, tolerability, and efficacy signals in patients with diabetic gastroparesis. Gastroparesis is a debilitating condition affecting gastric motility with limited treatment options and high unmet need. PCS12852 is designed to restore normal gastric emptying without the cardiovascular and central nervous system side effects seen with older agents in this class.
Lorin K. Johnson, Ph.D., Board Member and Scientific Advisor to Intact Therapeutics, stated, “The safety profile and high selectivity of PCS12852 make it a promising therapeutic option for patients with a wide range of GI motility disorders. The partnership between Intact and Processa will provide strategic alignment and shared upside to create value for both companies.”
The exclusive license will become effective upon completion of the definitive agreements and satisfaction of closing conditions, including an amendment of the license agreement between Processa and its licensor.
About Intact Therapeutics, Inc.
Intact Therapeutics is a clinical-stage biopharmaceutical company pioneering next-generation therapies for gastrointestinal (GI) disease, including products leveraging its proprietary thermal hydrogel technology. Intact spun out of Stanford University, and investors include Y Combinator, Encube Ethicals, and Brightstone Capital. The company has also received several non-dilutive grants from the NIH, NSF, and the California Institute of Regenerative Medicine, to further expand its treatment pipeline.
For more information, visit www.intacttherapeutics.com .
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com .
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties, which include, but are not limited to, statements regarding the Company’s expectations regarding the entry into a definitive license agreement with Intact. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
Company Contact:
Patrick Lin
(925) 683-3218
[email protected]
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
[email protected]
